BANGALORE - India's biotech major Biocon Friday entered into a strategic tie-up with the US-based Amylin Pharmaceuticals to jointly produce a peptide hybrid molecule for treating diabetes.
BANGALORE/ CALIFORNIA - Biocon, Limited (NSE: BIOCON) and Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) announced today that they have entered into an exclusive agreement to jointly develop, commercialize and manufacture a novel peptide therapeutic for the potential treatment of diabetes.
WASHINGTON - It's not just the size of the waist, but also the size of fat cells that play a major role in determining a women's risk for type 2 diabetes, according to a long-range study by Swedish researchers.
Older News
S M T W T F S
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30 31 1 2 3 4 5
6 7 8 9 10 11 12
Copyright© 2011 The Gaea Times